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Abstract
Background: Colorectal (CRC) carcinogenesis through various morphological stages has been linked to several
genetic and epigenetic changes. The Raf/MEK/ERK (MAPK) signal transduction cascade is an important mediator of
a number of cellular fates.
Methods: In this study, we investigated the presence of B-raf and K-ras mutations in 94 consecutive cases of
primary colon adenocarcinoma in correlation with the immunohistochemical expression of total and activated ERK
and the expression of mismatch repair proteins (MMR) hMLH1 and hMSH2 as well as their correlations with
standard clinicopathological parameters.
Results: The immunostaining pattern for total and activated ERK was nuclear and cytoplasmic. hMLH1 and hMSH2
proteins were preserved in 45/63 (71.43%) cases and 35/53 (66.04%) cases respectively. Total ERK nuclear
expression, was positively correlated with tumor stage (p = 0.049), whereas nuclear pERK expression was positively
correlated with histological grade (p = 0.0113) and tumor stage (p = 0.0952), although the latter relationship was
of marginal significance. DNA sequencing showed that 12 samples (12.7%) had a mutation in B-RAF Exon 15 and
none in Exon 11, whereas 22 (23.4%) had a K-ras mutation. Disruption of the MAP kinase pathway-either through
K-ras or B-raf mutation-was detected in 37% of all the examined cases, although the overexpression of total and
activated ERK1/2 was not correlated with the mutational status of K-ras or B-raf genes. Finally, the preservation of
hMLH1 or hMSH2 immunoexpression was not correlated with the presence of B-raf and/or K-ras mutations.
Conclusions: In this study, we present evidence that ERK activation occurs in a K-ras or B-raf -independent manner
in the majority of primary colon cancer cases. Moreover, B-raf mutations are not associated with mismatch-repair
deficiency through loss of hMLH1 or hMSH2 expression. Activated ERK could possibly be implicated in tumor
invasiveness as well as in the acquisition of a more aggressive phenotype.
Background
Colon cancer is the fourth most common malignancy in
terms of both incidence and mortality worldwide [1].
The development of colon cancer is a complex multi-
step process dependent on both genetic and environ-
mental factors, in which oncogenes, tumor suppressor
genes as well as genes involved in DNA damage
recognition and repair have been implicated. Gaining
insight into the molecular pathways involved in the pro-
gression of colon cancer is imperative for the develop-
ment of innovative individualised cancer treatment
strategies.
Colorectal (CRC) carcinogenesis through various mor-
phological stages has been linked to several genetic and
epigenetic changes. Until recently, two main pathways
of sporadic colorectal carcinogenesis were proposed: a)
t h ec h r o m o s o m a li n s t a b i l i t y( C I N )p a t h w a yw h i c h
affects proto-oncogenes and tumor suppressor genes
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number and structure, and b) the microsatellite instabil-
ity (MSI) pathway, responsible also for Lynch syndrome
CRCs, which features size variations of repeated nucleo-
tides (microsatellites) mainly in non coding sequences,
due to defects in the mismatch repair system (hMLH1,
hMSH2, mHMS6, PMS1, PMS2) [2,3]. In addition to
CIN and MSI pathways, a third pathway, the epigenetic
instability, which is thought to be largely driven by
hypermethylation-induced silencing of tumor suppres-
sor-like genes, has been implicated in the progression of
colorectal carcinogenesis [4]. According to this notion,
contemporary literature suggests that CRC in general
develops through two independent pathways that
involve sequences of genetic and epigenetic alterations
associated with pathological and clinical features: the
adenoma pathway in 70-80% and the newly recognized,
the serrated pathway in the remaining 20-30% [5]. The
somatic molecular features which characterize the newly
introduced serrated pathway to CRC include activating
mutations in B-raf [6] and widespread hypermethylation
of gene promoters (CIMP) [7] with or without MSI [6].
The kinases of mitogen-activated protein (MAP)
kinase superfamily participate in signaling cascades con-
served through evolution, which transduce extracellular
signals into intracellular responses. MAP kinases are
major components of pathways controlling embryogen-
esis, cell differentiation, proliferation and death. The
Ras/Raf/mitogen-extracellular signal-regulated kinase 1/
2 (MEK1/2)/extracellular signal regulated kinase 1/2
(ERK1/2) cascade is activated by mitogenic factors, dif-
ferentiation stimuli and cytokines [8,9]. The Raf family
of protein kinases, which is one class of Ras effectors,
phosphorylates the dual specific MAP kinases MEK1
and MEK2, which in turn phosphorylate and activate
the effector MAP kinases ERK1 and ERK2 [9]. ERKs are
multifunctional serine/threonine kinases that target a
vast array of substrates localized in all cellular compart-
ments, such as protein kinases, signaling effectors,
receptors, cytoskeletal and nuclear proteins and tran-
scription factors, that can influence cell fate [9-11].
Importantly, MAP kinases are capable of affecting
gene expression via intermediary kinases by phosphory-
lating proteins in the cytoplasm, but also translocate to
the nucleus, a critical step for the fulfilment of many
cellular functions of ERK, such as gene transcription,
cell proliferation and differentiation [12]. Through phos-
phorylation of these various substrates, constitutively
activated ERKs are able to influence many of the hall-
marks of carcinogenesis, as defined by Hanahan and
Weinberg [13]. Constitutive activation of this pathway
has been observed in several human malignancies and
cell lines such as breast, colon, thyroid carcinomas and
melanomas and provides a potent promitogenic force
resulting in uncontrolled proliferation and differentia-
tion [14,15].
The current study investigates the presence of muta-
tions in K-ras and B-raf genes in colorectal carcinoma,
in correlation with MAP kinase ERK expression and the
expression of mismatch repair proteins (MMR) hMLH1
and hMSH2, attempting to elucidate the involvement of
these MAP kinases in the development of colorectal
cancer, as well as their correlations with standard clini-
copathological parameters.
Methods
Patients
This is a retrospective study of 94 consecutive cases of
primary colon adenocarcinoma (53 men and 41 women,
median age of 60 years -range 35 to 82) for whom
archival material from primary tumor resection surgical
specimens was available. None of the patients had
received chemotherapy or radiation before surgery. All
cases were reviewed by two experienced pathologists
(PK, GL) and assigned a histological grade according the
standards laid down in the latest WHO classification of
colon carcinoma [16]. There were 10 grade 1, 64 grade
2 and 20 grade 3 carcinomas. According to the latest
TNM system of cancer staging adopted by the American
Joint Committee on Cancer and the International Union
Against Cancer (AJCC/IUCC), tumors were classified as
stage I: 7 cases (T1N0M0, T2N0M0), stage II: 36 cases
[stage IIA (T3N0M0), IIB (T4aN0M0) IIC (T4cN0M0),
stage III: 47 cases [stage IIIA (T1-T2N1M0, T1N2aM0),
IIIB (T3-T4aN1M0, T2-T3N2aM0, T1-T2N2bM0) and
IIIC (T4aN2aM0, T3-T4aN2bM0, T4bN1-2M0)] and
stage IV:4 (Any T Any N M1) cases.
Immunohistochemical analysis
Immunohistochemical analysis was performed in the
same blocks that were used for molecular analysis.
Accordingly, the tumor tissue that was available for
immunohistochemistry was exhausted in some cases.
Thus, the immunohistochemical expression of ERK pro-
tein was available in a subset of 55 specimens, the
expression of pERK protein in 45 specimens, the expres-
sion of hMLH1 in 63 cases and the expression of
hMSH2 in 53 cases. However, the distribution of muta-
tions in K-ras and B-raf (exon 15 or 11) did not differ
among the specimens for which immunohistochemical
analysis was available and those that immunohistochem-
i s t r yw a sn o ta v a i l a b l e ,af a c tt h a ts u g g e s t st h a tt h e r e
was not any significant bias in this regard. ERK and
pERK immunostaining was performed using a rabbit
polyclonal (#9488, p44/42 MAP kinase, Cell Signaling,
Beverly, MA) for ERK1/2 and a mouse monoclonal anti-
body (sc-7383, (E-4) Santa Cruz Biotechnology, Inc.,
California, USA) for pERK, whereas hMLH1 and
Levidou et al. World Journal of Surgical Oncology 2012, 10:47
http://www.wjso.com/content/10/1/47
Page 2 of 11hMSH2 immunostaining using mouse monoclonal anti-
bodies (#554073, G168-15 for hMLH1, Pharmingen, San
Diego, California and clone GB-12, for hMSH2, Onco-
gene Cambridge, MA). Sections (3 to 4 μm) were depar-
affinized, rehydrated, immersed in 3% H2O2 for 30 min
and microwaved at 750 W in 0.01 M citrate buffer (pH
6.0) for 15 min and left to cool down in TBS. Sections
were incubated with ERK. pERK, hMLH1 and hMSH2
antibodies overnight at room temperature (37°C), at a
dilution 1:100, 1:350, 1:180 and 1:180 respectively.
Immunostaining was performed using the standard avi-
din-biotin complex (Ultra Vision Polymer, LabVision)
and visualized with diaminobenzidine tetrahydrochloride
solution.
Light microscopic evaluation of immunostained slides
was performed independently by three (PK, NK, GL)
experienced pathologists without previous knowledge of
the clinical information. If a discrepancy occurred
between the three assessments, the slides were reas-
sessed jointly. In each case 1000-1500 neoplastic cells
throughout the section were counted at high-power
magnification. Nuclear and cytoplasmic pERK and ERK
expression were evaluated separately. Nuclear or cyto-
plasmic pERK and ERK labeling index was defined as
the percentage of neoplastic cells with nuclear or cyto-
plasmic immunoreactivity out of the total number of
neoplastic cells counted. According to the percentage of
positively stained neoplastic nuclei, each case was con-
sidered to display reduced (< 20%) or preserved (≥20%)
expression of hMSH2 and hMLH. This is an arbitrary
cut-off chosen for the purposes of this study, since no
uniform threshold has been established in the respective
literature. In this context studies evaluating the expres-
sion of MMR proteins in colorectal cancer have used
cut-offs ranging from 5-50%, whereas in other tumors
the more frequently cut-off value used is 20% [17-21].
Genomic DNA isolation
15 μm sections were used for DNA extraction. The
samples were digested overnight at 55°C using 200 μlo f
digestion buffer consisting of 50 mM Tris, 1 mM
EDTA, 0.5% SDS and 200 μg/ml Proteinase K. Genomic
DNA was extracted with phenol-chloroform and preci-
pitated in ice-cold ethanol. The DNA was redissolved in
distilled water and quantified by spectrophotometry at
260 nm under UV light.
PCR
200 ng of total DNA were amplified in a 50 μl reaction
mixture containing 25 pmoles of each primer, 25 mM
each dNTP, 1.5 mM MgCl2, 1 mM KCl, 0.1% gelatin
and 1.5 U Taq DNA polymerase (Advantage, Clontech,
Takara, USA). The profile used in the Progene Techne
thermal cycler was: 5 min at 95°C once; 30 sec at 95°C,
40 sec at 52-56°C, 1 min at 72°C for 40 cycles; 7 min at
72°C once. Sequences of the primers used are the
following:
K-ras: F -actgaatataaacttgtggtagttggacct-
K-ras: R -tcaaagaatggtcctggacc-
B-raf exon 15: F- TCA TAA TGC TTG CTC TGA
TAG GA-
B-raf exon 15: R- GGC CAA AAA TTT AAT CAG
TGG A-
RFLP analysis
5-10 μl aliquots of the PCR product were digested with
BstNI to reveal the presence of mutations in codon 12
of K-ras gene. Incubation was performed at 60°C for 3
hrs. The digestion products were then visualized by ethi-
dium bromide staining under UV light after electrophor-
esis on a 4% (3:1 Nusieve agarose) gel (Lonza, Cologne,
GmbH). The size of the PCR product for K-ras amplifi-
cation is 157 bp and includes two restriction sites for
BstNI restriction endonuclease. Thus the normal K-ras
allele is indicated by the presence of a 114 bp band in
the gel whereas the mutant K-ras allele by a 143 bp
band. Heterozygous mutant cases display both bands of
143 bp and 114 bp
SSCP analysis
PCR products were screened for mutations in exons 11
and 15 of the B-raf gene. Firstly, PCR products were
diluted in 10 μl formamide-dye solution (95% forma-
mide, 20 mM EDTA, 0.05% bromophenol blue, 0.05%
xylene cyanol), denatured for 7 min at 95°C and kept on
ice until loaded onto a 0,5× MDE gel (BMA, USA).
Electrophoresis was carried out at 3 W for 16-18 hours
at 4°C. After electrophoresis, the gel was silver stained
and examined for abnormal band patterns. The analysis
of all cases displaying abnormal band patterns was
repeated at least twice.
Sequencing
For B-raf mutation analysis the Big Dye terminator cycle
sequencing kit was used. The aberrant SSCP cases were
sequenced at least twice on an ABI prism 310 Genetic
analyzer (Perkin-Elmer, California, USA). PCR primers
were used for sequencing as well.
Statistical analysis
In the basic statistical analysis pERK and ERK nuclear or
cytoplasmic expressions were treated as continuous vari-
ables, whereas hMLH1 and hMSH2 expression levels
were treated as categorical variables. The relationships
among ERK, pERK, hMLH1, hMSH2 expression and
clinicopathological parameters, such as grade and stage
were tested with non parametric tests (Spearman corre-
lation coefficient, Kruskal-Wallis ANOVA and Mann
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tions among mutation status (regarding K-ras or B-raf)
and clinicopathological or immunohistochemical data
were calculated using Fisher’s exact test or Mann-Whit-
ney U test. Statistical calculations were performed using
the Statistical package STATA 9.0 for Windows. All
results with a two-sided p ≤ 0.05 were considered statis-
tically significant.
Results
Expression of ERK, pERK, hMLH1 and hMSH2 in colorectal
carcinomas (Figure 1)
The detailed results of immunohistochemical analysis are
shown in Additional file 1. The immunostaining pattern
for ERK was nuclear and cytoplasmic. All cases (55/55) dis-
played either nuclear and/or cytoplasmic immunostaining.
Nuclear immunoreactivity for ERK was detected in 85%
(47/55) of cases, whereas cytoplasmic immunoreactivity in
92.7% of cases (51/55). In 43 cases (78.18%) concurrent
cytoplasmic and nuclear positivity was recorded. pERK
immunoreactivity was mainly nuclear found in 68.89% (31/
45) of cases, while a small proportion of specimens dis-
played (11 cases, 24.4%) cytoplasmic positivity. In eight of
these cases (17.78%) there was simultaneous nuclear and
cytoplasmic pERK immunoexpression. Normal colorectal
mucosa was present in 39 of the 55 examined slides and
displayed membranous ERK immunoreactivity in the apical
aspect of the superficial epithelium.
Figure 1 A. Grade 1, stage I colorectal carcinoma, displaying minimal nuclear pERK staining. B. Grade 3, stage III colorectal carcinoma,
displaying increased nuclear pERK staining. C, D. ERK nuclear and cytoplasmic immunoreactivity in grade 1, stage II (C) and grade 3, stage III
with production of extra-cellular mucin (D).
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among tissue samples. We found that 13 samples had
no expression (12.73%), 22 had a weak expression (40%,
from 1 up to 15%), 13 had moderate expression
(23.64%, from 15 up to 50%), whereas 13 had strong
immunoexpression (23.64%, > 50%). Cytoplasmic immu-
noreactivity of ERK was in higher levels, since the
majority of samples (40 in 55 cases, 72.73%) displayed
strong positivity (> 50%). Most samples with strong
cytoplasmic expression displayed increased nuclear
expression, an observation which was confirmed with
the calculation of the Spearman’s correlation coefficient
(rho = 0.3361, p = 0.0121).
pERK nuclear and cytoplasmic immunoexpression dis-
played a narrower range of variation, ranging from no
expression up to 20% and 15% of tumor cells respec-
tively. Also, there was no significant correlation between
pERK nuclear and cytoplasmic expression (Spearman’s
correlation coefficient, p > 0.10). Normal colorectal
mucosa showed minimal nuclear pERK expression
whereas there was diffuse cytoplasmic pERK expression
(results available in 36 cases in which there was normal
mucosa adjacent to the tumor).
Additionally, there was no correlation between nuclear
or cytoplasmic ERK labelling index and the presence of
n u c l e a ra n d / o rc y t o p l a s m ic pERK immunoexpression
(Mann Whitney U test, p > 0.10).
As far as hMLH1 and hMSH2 protein expression is
concerned, it was preserved in 45/63 (71.43%) cases and
35/53 (66.04%) cases respectively. Adjacent normal
colorectal mucosa preserved the expression of hMLH1
(available in 44 cases) and hMSH2 (available in 36
cases).
Associations between ERK, pERK, hMLH1 and hMSH2 with
clinicopathological features
A significant association emerged between tumor’ss t a g e
and ERK nuclear expression levels, suggesting lower
expression levels (< 15%) in advanced tumors (Fisher’s
exact test, p = 0.049, Table 1). However, ERK nuclear
immunoexpression was not correlated with histological
grade, tumor location (Kruskal Wallis ANOVA, p >
0.10, Table 1) patients’ gender or age (Spearman, p >
0.10, Table 1). Moreover, cytoplasmic ERK immunoreac-
tivity was not correlated with any of the examined clini-
copathological parameters (p > 0.10, Table 1).
pERK nuclear immunoreactivity was positively corre-
lated with tumor grade (I vs II/III, Mann Whitney U
test, p = 0.0113, Table 2, Figure 2). Thus, grade (II and
III) tended to display higher pERK nuclear immunoreac-
tivity levels. Accordingly, pERK nuclear immunoreactiv-
ity was mainly reported in advanced stage tumors
(Fisher’s exact test, p = 0.0952, Table 2), although this
relationship was of marginal significance. The relation-
ships between nuclear pERK expression levels and
tumor location or patients’ age, as well as pERK cyto-
plasmic immunoreactivity and all clinicopathological
features failed to attain statistical significance (p > 0.10,
Table 2). On the contrary the preservation of hMLH1
and hMSH2 expression was not correlated with tumor’s
Table 1 Associations between nuclear ERK expression and clinicopathological parameters in 55 patients with
colorectal carcinoma.
Variables ERK nuclear ERK cytoplasmic expression
N Low expression group (<
15%)
High expression group
(≥15%)
p-
value
Low expression group (<
50%)
High expression group
(≥50%)
p-
value
Gender
Male 33 16 17 0.99 7 26 0.235
Female 22 10 12 8 14
TNM stage
I 4 0 4 0.049 2 2 0.298
II-IV 51 26 25 13 38
Grade
I 23 20 25 > 0.10 10 33 0.404
II/III 8 4 4 3 5
Tumor
location
Right colon 30 17 13 7 23 0.551
Left colon 25 9 16 0.99 8 17
Median (range) Median (range) Median (range) Median (range)
Age (years) 55 66.5 (51-77) 61 (35-83) 0.5562 59 (56-76) 66.5 (35-83) 0.5622
Results of Fisher’s exact test.
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and gender (p > 0.10, table 3).
Associations between ERK, pERK, hMLH1 and hMSH2
expression levels with B-RAF and/or K-RAS mutational
status
The results of molecular analysis are shown in Addi-
tional file 1. Of the 94 samples, 12 had a mutation in B-
raf Exon 15 (Figure 3a,b) and none in Exon 11, whereas
22 had a K-ras mutation (Figure 4). In the subset of 55
specimens that were available for immunohistochemical
evaluation of ERK protein tissue expression 4 had a B-
raf and 14 a K-ras mutation (Table 4). Most of the cases
with nuclear and cytoplasmic ERK expression did not
have a K-RAS mutation (79.09%, 34/43), although this
observation was not statistically significant (Table 4).
The same applied to the cases with the presence of
either nuclear (77.08%, 37/48) or cytoplasmic (76%, 38/
50) expression. Moreover, three of the 4 cases with B-
raf mutation had positive nuclear and cytoplasmic ERK
expression (75%), whereas the fourth displayed only
nuclear immunoreactivity. Importantly, the presence of
either B-raf or K-ras mutation was marginally associated
with the presence of cytoplasmic ERK expression (Fish-
er’s exact test, p = 0.097), suggesting that the proportion
of cytoplasmic ERK positivity is marginally higher in the
mutated cases when compared to the unmutated ones.
In the subset of 45 specimens that were available for
pERK immunohistochemical assessment, only 5 had a
B-raf mutation whilst 10 had a K-ras mutation (Table
4). There was no difference in the distribution of K-ras
mutations among the cases that showed nuclear and/or
cytoplasmic pERK expression. Furthermore, all cases
displayng cytoplasmic (11 cases) or both cytoplasmic
and nuclear (8 cases) pERK expression had a wild-type
B-raf. However, the presence of pERK immunoexpres-
sion, either nuclear or cytoplasmic was not correlated
with the presence of either B-raf or K-ras mutations
(Mann Whitney U test and Fisher’s exact test, p > 0.10).
In the subset of the 63 patients for whom hMLH1
expression was available, 17 had a K-ras (12 of which
preserved hMLH1 expression) and 7 a B-raf mutation (4
of which preserved hMLH1 expression) (Table 4).
Accordingly, 64.71% of the cases (11/17) with K-ras
mutation and 37.5% of the cases (3/8) with B-raf muta-
tion preserved hMSH2 immunoreactivity (Table 4).
However, the presence of hMLH1 or hMSH2 immu-
noexpression, was not correlated with the presence of
B-raf and/or K-ras mutations (p > 0.10). Finally, the pre-
sence of K-ras and/or B-raf mutations could not be
related to grade and stage (p > 0.10).
Discussion
Various molecular markers have been proposed for the
classification of colon cancer with regard to clinical
course and outcome, including cell cycle as well as
apoptotic regulators (c-FLIP, Ki67, COX-2) [22,23].
Deregulation of the MAPK signalling pathway has often
been associated with oncogenic transformation [24]. In
this regard, there is accumulating evidence involving
ERK activation in the tumorigenesis of various human
cancers such as prostate, breast, colon and ovary
[25-29]. Furthermore, activating B-raf mutations are
Table 2 Associations between nuclear and cytoplasmic
pERK expression and clinicopathological parameters in
45 patients with colorectal carcinoma.
pERK nuclear LI pERK cytoplasmic LI
N Median Range P
value
Median Range P
value
Gender
Male 24 1 0-15 0 0-10
Female 21 1 0-20 0.6999 0 0-15 0.9518
Histological
grade
I 4 0 0-0 0 0-0
II/III 41 1 0-20 0.0113 0 0-15 0.2504
TNM stage
I 5 0 0-10 0 0-0
II-IV 40 0-20 0.0952 0 0-15 0.1873
Tumor
location
Right colon 33 1 0-20 1 0-20
Left colon 12 1 0-10 0.3941 5 0-10 0.4452
Age (years) 45 R = 0.3941, p = 0.5687 R = 0.3153, p = 0.1529
Results of Mann Whitney U test.
Figure 2 Schematical representation of the association
between nuclear pERK expression and histological grade.
Tumors with grade II/III tended to display higher pERK nuclear
immunoreactivity compared to those with grade I (p = 0.0113,
Mann- Whitney U test).
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melanomas, thyroid and colon carcinomas implying
their significance as potential targets for anticancer
treatment [30,31]. In the present study we used immu-
nohistochemistry to examine the expression of total and
activated ERK1/2 in a panel of 94 colorectal carcinomas
in parallel with the expression of two MMR proteins
(hMLh1 and hMSH2), as well as K-ras and B-raf muta-
tions, which may lead to constitutive activation of
MAPK pathway.
To the best of our knowledge, this appears to be the
first study examining ERK expression in mismatch
repair deficient and mismatch repair proficient colorec-
tal cancer simultaneously with upstream gene alterations
such as K-ras and B-raf mutations, which contribute to
MAPK activation. In our cohort, ERK immunoreactivity
was observed in the cytoplasm as well as in the nucleus
in the majority of the cases (93% and 91% respectively).
More than 78% of the examined cases displayed concur-
rent ERK nuclear and cytoplasmic immunoreactivity, in
concordance with previous observations [29,30].
Increased levels of nuclear ERK positivity correlated
with strong cytoplasmic ERK expression. The observed
correlation between nuclear and cytoplasmic expression
as well as the concurrent nuclear and cytoplasmic
immunolocalization of ERK in the present series is com-
patible with its multiple functions targeting proteins
localized in the cytoplasm as well as the nucleus of the
cell. Moreover, pERK immunoreactivity was predomi-
nantly nuclear (68%) whereas cytoplasmic positivity was
Table 3 Associations between hMLH1 and hMSH2 expression and clinicopathological parameters in 53 and 63 patients
with colorectal carcinoma respectively.
Variables hMLH1 expression hMSH2 expression
N Reduced (< 20%) Preserved (≥20%) p-value N Reduced (< 20%) Preserved (≥20%) p-value
Gender
Male 34 10 24 0.99 30 10 20 0.99
Female 29 8 21 23 8 15
TNM stage
I 5 1 4 0.99 6 3 3 0.397
II-IV 58 17 41 47 15 32
Grade
I 8 1 7 0.421 6 2 4 0.99
II/III 55 17 33 47 16 31
Tumor location
Right colon 36 11 25 33 11 22 0.99
Left colon 27 7 20 0.782 20 7 13
Median (range) Median (range) Median (range) Median (range)
Age (years) 63 58 (53-73) 63(40-83) 0.2558 60(45-83) 60(40-81) 0.9607
Results of Fischer’s exact test.
Figure 3 A. Representative SSCP* analysis of B-raf gene, exon 15 of seven colorectal cancer cells. Lanes 1, 3-7: tumor samples with normal
band pattern (black arrows). Lane 2: tumor sample with the typical band pattern of a V600E mutation (arrow heads). *SSCP: Single strand
conformation polymorphism. B. Sanger heterozygous analysis showing a heterozygous B-raf mutation (exon 15) at codon 600 (p.V600E, c.1799T > A).
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is in line with previous investigations in colon as well as
other neoplasms, namely, endometrial, head and neck
tumors and melanomas [27,29,32,33]. Additionally, total
nuclear or cytoplasmic ERK staining was independent of
nuclear or cytoplasmic pERK status, in our cohort. This
observation is in agreement with previous studies in non
small cell lung and endometrial cancer as well as in
melanomas and could been explained by the hypothesis
that pERK immunopositivity could arise due to ERK
hyperactivation rather than overexpression [29,30,32].
Furthermore we show that high nuclear, but not cyto-
plasmic, ERK immunopositivity is correlated with tumor
stage (Table 1). Interestingly, our results demonstrate
that nuclear pERK expression parallels tumor grade and
tumor stage (Table 2, Figure 2) in keeping with findings
of previous studies in NSCLC and prostate cancer
[30,34]. This observation is in contrast with a previous
investigation [25] in which pERK expression was not
Figure 4 Mutational analysis of K-ras codon 12 by PCR-RFLP
(digestion with BSTNI restriction endonuclease). PCR product
size: 157 bp, Normal K-ras allele: 114 bp, Mutant K-ras allele: 143 bp.
Heterozygous mutant case: 143 bp and 114 bp. Μ = molecular
weight marker pUC Mix 8. Lane 1 = Undigested PCR product (157
bp). Lanes 7-9 = Mutant samples (143 bp and 114 bp). Lanes 2-6 &
10 = Normal samples (114 bp).
Table 4 Correlations of the presence of K-ras and B-raf mutations (exon 15) with immunohistochemical results in
patients for whom staining data were available.
K-ras Mutation B-raf Exon 15 mutation
Absent Present p Absent Present p
ERK nuclear expression (n = 55)
Absent 4 3 7 0
Present 37 11 0.354 44 4 0.99
ERK cytoplasmic expression (n = 55)
Absent 3 2 4 1
Present 38 12 0.592 47 3 0.325
ERK nuclear and cytoplasmic expression (n = 55)
Absent 7 5 11 1
Present 34 9 0.259 40 3 0.99
pERK nuclear expression (n = 65)
Absent 11 3 13 1
Present 24 7 0.99 27 4 0.99
pERK cytoplasmic expression(n = 65)
Absent 27 7 29 5
Present 8 3 0.687 11 0 0.313
pERK nuclear and cytoplasmic expression (n = 65)
Absent 29 8 32 5
Present 6 2 0.99 8 0 0.357
hMLH1 expression (n = 63)
Reduced 13 5 15 3
Preserved 33 12 0.99 41 4 0.397
hMSH2 expression (n = 53)
Reduced 12 6 13 5
Preserved 24 11 0.99 32 3 0.104
Results of Fischer’s exact test.
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studies in various other tumors (breast, pancreatic,
endometrial and ovarian cancer) that have failed to sub-
stantiate a positive correlation between pERK expression
and classical clinicopathological parameters
[26,32,35-37]. Taking into account that in our study
normal colorectal mucosa displays minimal nuclear
pERK expression, our results speak in favor of the
potential role of this molecule in tumor evolution as
well as, in the acquisition of a more aggressive pheno-
type in colorectal carcinogenesis. Along this line, it has
been suggested that constitutively active ERKs are cap-
able of affecting gene expression, being able to influence
many of the hallmarks of carcinogenesis [35]. It could
be hypothesised that as colorectal cancer progresses to a
more advanced disease, an increase in the activation of
the MAP kinase signal transduction pathway occurs
[34]. Unfortunately, the statistical power of the present
investigation is reduced due to the small cohort of
pERK positive cases. Further studies of larger cohorts
are warranted to confirm our results. Along this line,
pERK expression has been shown to be associated with
poor prognosis in colorectal carcinomas [27]. It has
been speculated that the activation of the MAPK path-
way initiates cellular processes, which could result in
either favorable or worse clinical outcome, a fact due to
the complex signal transduction network ERKs are
involved in. In fact, adverse effects can be observed,
depending on the intensity and duration of the promito-
genic signal [10].
The aforementioned findings are quite significant in
view of the fact that protein kinases represent a group
of molecular targets characterized by a cancer specific
potential, allowing the development of new generation
chemotherapeutic agents acting as kinase inhibitors. The
first oral multi-kinase inhibitor that targets Raf kinases
have already been approved for the treatment of renal
cell cancer, whereas these factors display a broad spec-
trum antitumor activity in colon, breast and non-small-
cell lung cancer in xenograft models and also hepatocel-
lular carcinoma and sarcoma [38,39]. In this context,
the presence of B-raf mutations has been suggested as a
possible surrogate marker of sensitivity to those drugs
which target the ERK pathway at the level of Raf kinase
[38,39].
The frequency of K-ras mutations detected in this
study (about 23% of the examined cases) was compar-
able to that found in previous reports (Table 4) [39-41].
Furthermore, the presence of B-raf mutations in color-
ectal cancer is estimated to be about 10% of unselected
colorectal cancers [42-44]. In particular, B-raf T1799A
mutation (V600E) has been reported in 4% of microsa-
tellite stable (MSS) tumors whereas in microsatellite
unstable tumors the percentage rises up to 27-52%
[42,44-46]. By analogy to those investigations we
detected V600E B-raf mutations in about 7% of MSS
tumors and in 21% of MSI unstable tumors. Interest-
ingly, our cases exhibited only either B-raf or K-ras
mutations in accordance with previous observations sug-
gesting that these are mutually exclusive defects that
probably exert equivalent effects in tumorigenesis
[39,46].
Moreover, in our series the expression levels of total
and activated ERK1/2 were independent of the mutation
status of B-raf and K-ras genes. These results are in
favor of the view that constitutive pERK activation
occurs in a K-ras or B-raf -independent manner in a
large subset of primary colon cancer cases. Recently,
several negative regulators of the MAPK signalling path-
way upstream of ERK at the level of Raf were identified,
including Sprouty and Spred. Activation of these nega-
tive regulators inhibits phosphorylation of ERK1/2, even
in the presence of mutation in K-ras gene [32,47]. This
finding has also previously been observed in ulcerative
colitis-related carcinomas [ 4 8 ] .T h eg e n e t i cn a t u r eo f
constitutive activation of the RAS/RAF/MEK/ERK path-
way in colorectal tumors with no B-raf or K-ras muta-
tion remains unknown, although it may in part due to
increased activity of growth factor receptor induced cell
proliferation pathways. It could be speculated that in
cancer constitutive activation of MAP kinase could be
triggered by upstream oncogenic regulators due to the
presence of paracrine/autocrine growth factor stimula-
tion, rather than Ras or B-raf mutations or components
of the various other signal transduction pathways that
interact with MAPK, since the mutation of K-ras and B-
raf obviously constitutes one of multiple ways to activate
this pathway.
In sporadic colorectal carcinogenesis B-raf mutations
like K-ras mutations appear to occur early at the transi-
tion from small to medium size adenoma and are extre-
mely frequent in so-called serrated adenomas [49].
According to the MSI colorectal pathway, MSI in spora-
dic tumors has been suggested to be mostly due to
hypermethylation of the promoters of MMR genes and
is correlated with B-raf mutations (44). However, in our
study B-raf mutations were not correlated with loss of
hMLH1 or hMSH2 protein, suggesting that the B-raf
mutated cases of our cohort may belong to more than
one colorectal carcinogenesis pathways.
Conclusions
In this study, we have shown that mutations of the B-raf
gene are not associated with mismatch-repair deficiency
through loss of hMLH1 or hMSH2 expression. Disrup-
tion of the MAP kinase pathway-either through K-ras or
B-raf mutation-was detected in 37% of all the examined
cases, although the overexpression of total and activated
Levidou et al. World Journal of Surgical Oncology 2012, 10:47
http://www.wjso.com/content/10/1/47
Page 9 of 11ERK1/2 was not correlated with the mutational status of
K-ras or B-Rraf genes. Interestingly, we present evidence
that the expression of activated ERK expression parallels
histological grade and stage in colon carcinomas, thus
being implicated in tumor invasiveness as well as in the
acquisition of a more aggressive phenotype. Our find-
ings encourage prospective investigations to further elu-
cidate and validate the potential role of pERK as a
prognostic factor and therapeutic target in colon
carcinogenesis.
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